Clinical Highlights
MITROFLOW LONG TERM RESULTS
MITROFLOW PERICARDIAL AORTIC VALVE REPLACEMENT: DURABILITY RESULTS UP TO 21 YEARS
C.A. Yankah, M.Pasic, M.Musci, J.Stein, C.Detschades, H.Siniawski, R.Hetzer
J Thorac Cardiovasc Surg. 2008 Sept; 136(3): 688-696
HAEMODYNAMIC RESULTS
CLINICAL RESULTS
Actuarial freedom from structural valve deterioration at 20 years
CONCLUSIONS
“The Mitroflow pericardial bioprosthesus exhibits very low pressure gradients combined with easy implantability. After two decades of follow-up, the Mitroflow pericardial aortic valve continues to be a valve of chioce with a predictable low rate of valve-related events, particularly for patients over the age of 65-70 and others with comorbidities.”
MITROFLOW PERICARDIAL AORTIC VALVE REPLACEMENT: DURABILITY RESULTS UP TO 21 YEARS
C.A. Yankah, M.Pasic, M.Musci, J.Stein, C.Detschades, H.Siniawski, R.Hetzer
J Thorac Cardiovasc Surg. 2008 Sept; 136(3): 688-696
| Number of patients | 1516 isolated AVR |
| Implant time frame | March 1986 - Dec 2007 |
| Mean age | 73.2 ± 0.22 |
| Distribution | 442 males (29.2%) 1071 females (70.8%) |
| Average follow up | 4.07 ± 0.12 yrs |
| Total Patient Years | 6163.5 |
| Follow up completion | 99.3% |
HAEMODYNAMIC RESULTS
CLINICAL RESULTS
Actuarial freedom from structural valve deterioration at 20 years
| EVENT | Linearized rate (%/pts-yr) | Actuarial Freedom From Event |
| Thromboembolic Events <65 yrs ≥65 yrs | 0.79 0.50 0.93 | 94.1% - - |
| Bleeding | 0.065 | - |
| Endocarditis | 0.28 | 96.8% |
| Paravalvular Leaks | 0.016 | - |
| Valve Related Death | 0.40 | 82.9% |
CONCLUSIONS
“The Mitroflow pericardial bioprosthesus exhibits very low pressure gradients combined with easy implantability. After two decades of follow-up, the Mitroflow pericardial aortic valve continues to be a valve of chioce with a predictable low rate of valve-related events, particularly for patients over the age of 65-70 and others with comorbidities.”